Back to Search Start Over

The elevated preoperative fasting blood glucose predicts a poor prognosis in patients with esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study

Authors :
Binying Liang
Xiandong Lin
Chao Li
Wenquan Niu
Gang Chen
Feng Peng
Jinxiu Lin
Xuehong Liao
Hejun Zhang
Xiongwei Zheng
Dan Hu
Source :
Oncotarget
Publication Year :
2016
Publisher :
Impact Journals, LLC, 2016.

Abstract

// Dan Hu 1, * , Feng Peng 2, * , Xiandong Lin 1, * , Gang Chen 1 , Binying Liang 3 , Chao Li 1 , Hejun Zhang 1 , Xuehong Liao 1 , Jinxiu Lin 2 , Xiongwei Zheng 1 , Wenquan Niu 4 1 Department of Pathology, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China 2 Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China 3 Medical-Record Department, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China 4 State Key Laboratory of Medical Genomics, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China * Shared first authors Correspondence to: Feng Peng, email: pengfeng@medmail.com.cn Xiongwei Zheng, email: agu1960@126.com Wenquan Niu, email: niuwenquan_shcn@163.com Keywords: fasting blood glucose, esophageal squamous cell carcinoma, prognosis, mortality, FIESTA study Received: May 09, 2016 Accepted: July 28, 2016 Published: August 12, 2016 ABSTRACT Diabetes as a latent risk factor for cancer has been extensively investigated, while its postoperative prognosis for esophageal cancer is rarely reported. We therefore sought to assess whether the elevated fasting blood glucose before surgery was associated with poor survival in esophageal cancer patients by eliciting a subset of data from the ongoing F ujian prospect i ve inv est igation of c a ncer (FIESTA) study. Over 15-year follow-up, 2535 patients receiving three-field lymphadenectomy were assessable. Only patients with esophageal squamous cell carcinoma (ESCC) (n=2396) were analyzed due to the lower prevalence of the other histological types. In ESCC patients, the follow-up duration ranged from 0.5 to 180 months (median 38.2 months). The median survival time (MST) was remarkably shorter in males than in females (80.7 vs. 180+ months, Log-rank test: P

Details

ISSN :
19492553
Volume :
7
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....18f5fab745ce2f1ed936fb06156dfa83
Full Text :
https://doi.org/10.18632/oncotarget.11247